WHO ICTRP trial
A randomized, multicenter, positive drug controlled clinical study protocol to…
ChiCTR2200067227 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200067227 |
|---|---|
| Public title | A randomized, multicenter, positive drug controlled clinical study protocol to evaluate the efficacy and safety of adalimumab in adults with exanthematous and severe drug eruptions |
| Scientific title | A randomized, multicenter, positive drug controlled clinical study protocol to evaluate the efficacy and safety of adalimumab in adults with exanthematous and severe drug eruptions |
| Primary sponsor | The University of Hong Kong-Shenzhen Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | drug eruption |
| Interventions | Therapy group:Adalimumab;Control group:Methylprednisolone |
| Registration date | Dec 30, 2022 |
| Target size | Therapy group:80;Control group:80 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: